Novo Nordisk GLP-1s face renewed NAION scrutiny as India’s obesity-drug market accelerates
EMA labelling action and US litigation renew safety focus on semaglutide and other GLP-1 therapies. The risk lands as India’s GLP-1 market reaches ₹2,333 crore, with generic semaglutide broadening pharma and retail exposure.
What happened
Novo Nordisk’s GLP-1 drugs face renewed NAION safety scrutiny, EMA labelling action and US litigation. The risk is relevant to India’s rapidly expanding ₹2,333
Key facts
- 3 confirmed NAION cases among GLP-1 recipients versus 5 on inactive treatment
- 96,829 people in pooled analysis
- Over 58 million patient-years of post-marketing exposure
- EMA: NAION may affect up to 1 in 10,000 semaglutide users
- 216 US litigation actions pending as of September 1, 2026
- India GLP-1 market: ₹2,333 crore MAT in August 2026
- India semaglutide sales: ₹782 crore; tirzepatide sales: ₹1,456 crore
Why this matters
Potential GLP-1 partnerships or acquisitions in India warrant deeper diligence on pharmacovigilance, liability allocation and differentiation as generics expand distribution but intensify reputational exposure.